Lipocine announces tentative approval of tlando™

Salt lake city, dec. 8, 2020 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the u.s. food and drug administration ("fda") has granted tentative approval to tlando, its oral...
LPCN Ratings Summary
LPCN Quant Ranking